HighPoint Advisor Group LLC Makes New $447,000 Investment in DexCom, Inc. (NASDAQ:DXCM)

HighPoint Advisor Group LLC bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 3,606 shares of the medical device company’s stock, valued at approximately $447,000.

Other institutional investors also recently bought and sold shares of the company. DSM Capital Partners LLC purchased a new position in DexCom during the fourth quarter worth about $28,000. Valley National Advisers Inc. raised its stake in DexCom by 73.0% during the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after purchasing an additional 103 shares during the period. MV Capital Management Inc. raised its stake in DexCom by 99.3% during the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after purchasing an additional 138 shares during the period. Smithfield Trust Co increased its position in shares of DexCom by 103.1% during the fourth quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock valued at $40,000 after acquiring an additional 165 shares during the last quarter. Finally, Washington Trust Advisors Inc. increased its position in shares of DexCom by 120.6% during the fourth quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock valued at $44,000 after acquiring an additional 193 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

DXCM has been the subject of a number of recent analyst reports. Raymond James lifted their price target on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research report on Friday, April 26th. Canaccord Genuity Group lifted their price target on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, April 26th. Royal Bank of Canada initiated coverage on shares of DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target for the company. UBS Group lifted their price target on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Finally, StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research report on Monday, June 10th. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $140.94.

DexCom Stock Up 0.1 %

Shares of DexCom stock opened at $116.64 on Thursday. DexCom, Inc. has a 52-week low of $74.75 and a 52-week high of $142.00. The company has a 50 day moving average of $126.16 and a 200 day moving average of $125.92. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. The company has a market capitalization of $46.39 billion, a P/E ratio of 75.25, a P/E/G ratio of 2.85 and a beta of 1.22.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The company had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. As a group, research analysts forecast that DexCom, Inc. will post 1.78 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 4,137 shares of DexCom stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $140.00, for a total value of $579,180.00. Following the completion of the transaction, the executive vice president now owns 76,304 shares in the company, valued at $10,682,560. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Bridgette P. Heller sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $113.55, for a total transaction of $113,550.00. Following the completion of the sale, the director now owns 25,349 shares in the company, valued at approximately $2,878,378.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Sadie Stern sold 4,137 shares of the business’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $140.00, for a total transaction of $579,180.00. Following the sale, the executive vice president now owns 76,304 shares of the company’s stock, valued at approximately $10,682,560. The disclosure for this sale can be found here. Insiders sold 61,837 shares of company stock worth $8,490,675 over the last 90 days. 0.30% of the stock is owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.